Literature DB >> 24634859

Expression of IGFBP-6 in a proliferative vitreoretinopathy rat model and its effects on retinal pigment epithelial cell proliferation and migration.

Hong-Mei Zhao1, Min-Jie Sheng1, Jing Yu1.   

Abstract

AIM: To investigate the expression of insulin-like growth factor binding protein-6 (IGFBP-6) in a proliferative vitreoretinopathy (PVR) model and its effects on proliferation and migration in retinal pigment epithelial (RPE) cells.
METHODS: A PVR Wistar rat model was established by the intravitreal injection of RPE-J cells combined with platelet-rich plasma (PRP). The expression levels of IGFBP-6 were tested by ELISA. ARPE-19 cell proliferation was evaluated by the MTS method, and cell migration was evaluated by wound healing assays.
RESULTS: The success rate of the PVR model was 89.3% (25/28). IGFBP-6 was expressed at higher levels in the vitreous, serum and retina of rats experiencing advanced PVR (grade 3) than in the control group (vitreous: 152.80±15.08ng/mL vs 105.44±24.81ng/mL, P>0.05; serum: 93.48±9.27ng/mL vs 80.59±5.20ng/mL, P<0.05; retina: 3.02±0.38ng/mg vs 2.05±0.53ng/mg, P<0.05). In vitro, IGFBP-6 (500ng/mL) inhibited the IGF-II (50ng/mL) induced ARPE-19 cell proliferation (OD value at 24h: from 1.38±0.05 to 1.30±0.02; 48h: from 1.44±0.06 to 1.35±0.05). However, it did not affect basal or VEGF-, TGF-β- and PDGF-induced cell proliferation. IGFBP-6 (500ng/mL) reduced the IGF-II (50ng/mL)-induced would healing rate [24h: from (43.91±3.85)% to (29.76±2.49)%; 48 h: from (66.09±1.67)% to (59.88±3.43)%].
CONCLUSION: Concentrations of IGFBP-6 increased in the vitreous, serum, and retinas only in advanced PVR in vivo. IGFBP-6 also inhibited IGF-II-induced cell proliferation in a not dose or time dependent manner and migration. IGFBP-6 participates in the development of PVR and might play a protective role in PVR.

Entities:  

Keywords:  insulin-like growth factor binding protein-6; proliferative vitreoretinopathy; retinal pigment epithelial cells

Year:  2014        PMID: 24634859      PMCID: PMC3949454          DOI: 10.3980/j.issn.2222-3959.2014.01.05

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  33 in total

1.  Cross-talk between MAP kinase pathways is involved in IGF-independent, IGFBP-6-induced Rh30 rhabdomyosarcoma cell migration.

Authors:  Ping Fu; Guang Jun Liang; Sahil S Khot; Robert Phan; Leon A Bach
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

2.  Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo.

Authors:  M A Gallicchio; M Kneen; C Hall; A M Scott; L A Bach
Journal:  Int J Cancer       Date:  2001-12-01       Impact factor: 7.396

Review 3.  Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

Review 4.  Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.

Authors:  Venki Sundaram; Allon Barsam; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

Review 5.  Proliferative vitreoretinopathy: risk factors and pathobiology.

Authors:  J Carlos Pastor; E Rodríguez de la Rúa; Francisco Martín
Journal:  Prog Retin Eye Res       Date:  2002-01       Impact factor: 21.198

Review 6.  Proliferative vitreoretinopathy as a late complication of blunt ocular trauma.

Authors:  Tilena Waters; Lori Vollmer; Joseph Sowka
Journal:  Optometry       Date:  2008-04

Review 7.  Proliferative vitreoretinopathy: pathobiology and therapeutic targets.

Authors:  Yannek I Leiderman; Joan W Miller
Journal:  Semin Ophthalmol       Date:  2009 Mar-Apr       Impact factor: 1.975

8.  Promotion of cancer cell migration: an insulin-like growth factor (IGF)-independent action of IGF-binding protein-6.

Authors:  Ping Fu; Julian A Thompson; Leon A Bach
Journal:  J Biol Chem       Date:  2007-05-22       Impact factor: 5.157

Review 9.  Mechanisms in proliferative vitreoretinopathy.

Authors:  Ivana K Kim; Jorge G Arroyo
Journal:  Ophthalmol Clin North Am       Date:  2002-03

10.  Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy.

Authors:  Mojca Globocnik Petrovic; Peter Korosec; Mitja Kosnik; Josko Osredkar; Marko Hawlina; Borut Peterlin; Daniel Petrovic
Journal:  Mol Vis       Date:  2008-07-30       Impact factor: 2.367

View more
  7 in total

1.  The effects of pleiotrophin in proliferative vitreoretinopathy.

Authors:  Xue Ding; Yujing Bai; Xuemei Zhu; Tianqi Li; Enzhong Jin; Lvzhen Huang; Wenzhen Yu; Mingwei Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-01-12       Impact factor: 3.117

Review 2.  Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.

Authors:  Nalo Hamilton; Diana Marquez-Garban; Vei H Mah; Yahya Elshimali; David Elashoff; Edward B Garon; Jaydutt Vadgama; Richard Pietras
Journal:  Crit Rev Oncog       Date:  2015

3.  Effects of resveratrol on ARPE-19 cell proliferation and migration via regulating the expression of proliferating cell nuclear antigen, P21, P27 and p38MAPK/MMP-9.

Authors:  Xiao-Ning Hao; Wen-Jie Wang; Jian Chen; Qing Zhou; Yi-Xin Qu; Xiao-Yong Liu; Wei Xu
Journal:  Int J Ophthalmol       Date:  2016-12-18       Impact factor: 1.779

Review 4.  The Roles of Insulin-Like Growth Factor Binding Protein Family in Development and Diseases.

Authors:  Fei Song; Xiao-Xia Zhou; Yu Hu; Gang Li; Yan Wang
Journal:  Adv Ther       Date:  2020-12-17       Impact factor: 3.845

5.  Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy.

Authors:  Dhanesh Amarnani; Arturo Israel Machuca-Parra; Lindsay L Wong; Christina K Marko; James A Stefater; Tomasz P Stryjewski; Dean Eliott; Joseph F Arboleda-Velasquez; Leo A Kim
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-08-01       Impact factor: 4.799

6.  Protein Kinase A Inhibitor H89 Attenuates Experimental Proliferative Vitreoretinopathy.

Authors:  Yali Lyu; Wei Xu; Jieping Zhang; Mengwen Li; Qingyi Xiang; Yao Li; Tianhao Tan; Qingjian Ou; Jingfa Zhang; Haibin Tian; Jing-Ying Xu; Caixia Jin; Furong Gao; Juan Wang; Weiye Li; Ao Rong; Lixia Lu; Guo-Tong Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

7.  Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy.

Authors:  Santiago Delgado-Tirado; Dhanesh Amarnani; Guannan Zhao; Elizabeth J Rossin; Dean Eliott; John B Miller; Whitney A Greene; Leslie Ramos; Said Arevalo-Alquichire; David Leyton-Cifuentes; Lucia Gonzalez-Buendia; Daniela Isaacs-Bernal; Hannah A B Whitmore; Natalia Chmielewska; Brandon V Duffy; Eric Kim; Heuy-Ching Wang; Jose M Ruiz-Moreno; Leo A Kim; Joseph F Arboleda-Velasquez
Journal:  Sci Rep       Date:  2020-11-30       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.